MONTE ROSA THERAPEUTICS INC
MONTE ROSA THERAPEUTICS INC logo
GLUE

MONTE ROSA THERAPEUTICS INC (GLUE)

$7.025.77%

Market is closed
– opens on 8 PM, 31 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$6.91
Day's Range
$7.39
$6.05
52-Week Range
$15.54
1 month return9.77%
3 month return23.7%
1 year return44.55%
5 year return63.68%

Analyst Recommendation

based on 16 analysts ratings

Buy
75%
Buy
25%
Hold
0%
Sell

Based on 16 Wall street analysts offering stock ratings for MONTE ROSA THERAPEUTICS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 211.82%

Current

$7.02

Target

$21.89

Recommendation Trend

Based on 16 analyst

Current1M Ago3M Ago
Buy
12
12
11
Hold
4
4
4
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization360.6M
Book Value$6.02
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)5.09
PE Ratio1.46
Wall Street Target Price21.89

Valuation

Trailing PE1.46
Forward PE0.0
Price/Book (mrq)1.43
Enterprise Value188.8M
Enterprise Value/Revenue0.0
Enterprise Value/Ebitda-1.89

Technicals

50 Day MA8.17
200 Day MA8.86

Institutional Holdings

NEA Management Company, LLC

15.92%

FMR Inc

12.82%

T. Rowe Price Associates, Inc.

7.78%

BlackRock Inc

7.17%

venBio Select Advisor LLC

6.95%

Cormorant Asset Management, LLC

6.19%

Company Information

Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
OrganizationMONTE ROSA THERAPEUTICS INC
Employees118
CEODr. Markus Warmuth M.D.
IndustryHealthcare

Discover more

Frequently Asked Questions

What is MONTE ROSA THERAPEUTICS INC share price today?

Can Indians buy MONTE ROSA THERAPEUTICS INC shares?

How can I buy MONTE ROSA THERAPEUTICS INC shares from India?

Can Fractional shares of MONTE ROSA THERAPEUTICS INC be purchased?

What are the documents required to start investing in MONTE ROSA THERAPEUTICS INC stocks?

What are today’s High and Low prices of MONTE ROSA THERAPEUTICS INC?

What are today’s traded volumes of MONTE ROSA THERAPEUTICS INC?

What is today’s market capitalisation of MONTE ROSA THERAPEUTICS INC?

What is the 52 Week High and Low Range of MONTE ROSA THERAPEUTICS INC?

How much percentage MONTE ROSA THERAPEUTICS INC is down from its 52 Week High?

How much percentage MONTE ROSA THERAPEUTICS INC is up from its 52 Week low?

What are the historical returns of MONTE ROSA THERAPEUTICS INC?

Who is the Chief Executive Officer (CEO) of MONTE ROSA THERAPEUTICS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*